Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta‐analysis

@article{Katz2008LamivudinePR,
  title={Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta‐analysis},
  author={Lior H Katz and Abigail Fraser and Anat Gafter-Gvili and Leonard Leibovici and Ran Tur-kaspa},
  journal={Journal of Viral Hepatitis},
  year={2008},
  volume={15}
}
Summary.  To assess the effects of prophylactic lamivudine on reactivation and mortality following immunosuppressive therapy in hepatitis B surface antigen (HBsAg)‐positive patients, we performed a meta‐analysis. Systematic review and meta‐analysis of randomized and nonrandomized prospective controlled trials and retrospective comparative case series were identified through The Cochrane Hepato‐Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials, MEDLINE… 
Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation.
TLDR
The available evidence suggests that entecavir is more effective than lamivudine for preventing HBV reactivation and HBV-related hepatitis in patients with chronic or resolved HBV infection who are undergoing chemotherapy or immunosuppressive therapy.
 Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation.
TLDR
The available evidence suggests that entecavir is more effective than lamivudine for preventing HBV reactivation and HBVrelated hepatitis in patients with chronic or resolved HBV infection who are undergoing chemotherapy or immunosuppressive therapy.
Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy
TLDR
In lymphoma patients under chemotherapy treatment, entecavir is more effective than lamivudine in preventing hepatitis B reactivation and should be considered the primary preventive therapy for patients with advanced stage disease.
Hepatitis B virus management to prevent reactivation after chemotherapy: a review
TLDR
A narrative review of the existing evidence regarding screening for and management of HBV infection among patients with cancer showed inconsistencies in the definition and management strategies for HBV reactivation.
A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience
TLDR
Attention should be paid to HBV reactivation in patients with past as well as chronic HBV infection during and after rituximab therapy, as adherence to guidelines for screening and preemptive therapy for HBv reactivation was negligent among the included cohort.
Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis
TLDR
Tenofovir and entecavir might be the most potent regimes in prevention of HBV reactivation for CHB infected patients with hematological malignancies undergoing chemotherapy or HSCT by network meta-analysis.
Chemoprevention of Patients with Hepatitis B Receiving Chemotherapy or Bone Marrow Transplant
TLDR
Current literature and society guidelines on HBV reactivation, risk factors, and prophylaxis for HBV reactsivation in patients undergoing chemo-/immunosuppressive therapy are reviewed.
Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy
TLDR
Lamivudine prophylaxis reduced hepatic complications during adjuvant chemotherapy in patients with breast cancer and should be considered in HBsAg-positive patients with Breast cancer who are candidates for adjUvant chemotherapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 82 REFERENCES
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
  • W. Yeo, P. Chan, P. Johnson
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
Prophylactic lamivudine significantly reduced the incidence of HBV reactivation and the overall morbidity of cancer patients undergoing chemotherapy.
Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy
TLDR
Primary prophylaxis with lamivudine may be a well tolerated and effective method to reduce the frequency of chemotherapy‐induced HBV reactivation in chronic HBsAg carriers.
Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.
TLDR
Lamivudine should be considered preemptively before or at the initiation of chemotherapy for all hepatitis B surface antigen-positive lymphoma patients undergoing intense chemotherapy.
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo‐lipiodolization
TLDR
In conclusion, preemptive lamivudine therapy demonstrated excellent efficacy in reducing hepatitis due to HBV reactivation and hepatic morbidity during TACL and should be considered in HCC patients with an HBV DNA level of more than 104 copies/mL.
Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
  • L. Hsiao, T. Chiou, Po-min Chen
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2006
Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy
TLDR
In Hong Kong, where hepatitis B infection is endemic, it is proposed to screen all cancer patients for hepatitis B surface antigen before immunosuppressive/cytotoxic therapy, and to closely monitor liver function of those who are found to be HBsAg seropositive.
Steroid‐free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV‐carriers with lymphoma
TLDR
In conclusion, steroid‐free chemotherapy decreases the incidence and severity of HBV reactivation in HBsAg‐positive lymphoma patients, however, further research is needed to evaluate whether steroid-free chemotherapy may confer a less satisfactory control of lymphoma.
Lamivudine. A review of its therapeutic potential in chronic hepatitis B.
TLDR
Lamivudine inhibits HBV replication, reduces hepatic necro-inflammatory activity and the progression of fibrosis in patients with chronic hepatitis B, ongoing viral replication and compensated liver disease including HBeAg-negative patients.
Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
TLDR
Preemptive use of lamivudine effectively reduced hepatitis due to exacerbation of HBV (adjusted hazards ratio, 0.09; P = .021).
Lamivudine prophylaxis for prevention of chemotherapy‐induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies
TLDR
Prophylactic lamivudine treatment in HBV carriers with haemato/oncological malignancy receiving chemotherapy prevents chemotherapy‐induced HBV reactivation.
...
1
2
3
4
5
...